Citi lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $36 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
- Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
- Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
- Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
- Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA